Athira Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.

- Jefferies Healthcare Conference
- Goldman Sachs 42^nd Annual Global Healthcare Conference

BOTHELL, Wash., May 26, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42^nd Annual Global Healthcare Conference to be held June 8-11, 2021.

Details on the presentations can be found below.

Jefferies Healthcare Conference
Date: Wednesday, June 2, 2021
Fireside chat time: at 4:30 PM ET
Webcast: Click Here

Goldman Sachs 42^nd Annual Global Healthcare Conference
Date: Tuesday, June 8, 2021
Fireside chat time: at 5:30 PM ET
Webcast: Click Here

A webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Julie.rathbun@athira.com
206-769-9219

FAQ

When will Athira Pharma participate in the Jefferies Healthcare Conference?

Athira Pharma will participate in the Jefferies Healthcare Conference on June 2, 2021, with a fireside chat at 4:30 PM ET.

What date is the Goldman Sachs 42nd Annual Global Healthcare Conference?

The Goldman Sachs 42nd Annual Global Healthcare Conference is scheduled for June 8, 2021.

Who is presenting at the healthcare conferences for Athira Pharma?

Leen Kawas, Ph.D., President and CEO of Athira Pharma, will present at both healthcare conferences.

Where can I watch the webcasts for Athira Pharma's presentations?

Webcasts for Athira Pharma's presentations are available on their website, and archived replays will be accessible for at least 30 days.

What is the focus of Athira Pharma's research?

Athira Pharma focuses on developing small molecules to restore neuronal health and stop neurodegeneration, particularly for Alzheimer's and Parkinson's dementia.